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1  | INTRODUC TION
Idiopathic Parkinson’s disease (PD) is defined by clinical motor 
symptoms including hypokinesia, rigidity and tremor, which are 
mainly caused by a dopaminergic nigrostriatal deficit and are 
improved by dopaminergic, anticholinergic or NMDA receptor 
blocking drugs.1 More recently, recognition of the relevance of 
non-motor symptoms, which include depression, psychosis, im-
pulse control disorders, anxiety, sleep disorders and cognitive 
deficits, has been elucidated. Although the development of newer 
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Background: Idiopathic Parkinson’s disease (PD) is characterized by clinical motor 
symptoms including hypokinesia, rigidity and tremor. In addition to the movement 
disorder, cognitive deficits are commonly described. In the present study, we applied 
FP-CIT SPECT to investigate the impact of nigrostriatal dopaminergic degeneration 
on cognitive function in PD patients.
Methods: Fifty-four PD patients underwent [123I]FP-CIT SPECT and CERAD 
(Consortium to Establish a Registry for Alzheimer’s Disease) testing. FP-CIT SPECT 
visualized the density of presynaptic dopamine transporters in both striata, each sub-
divided into a limbic, executive and sensorimotor subregion according to the atlas 
of Tziortzi et al (Cereb Cortex 24, 2014, 1165). CERAD testing quantified cognitive 
function.
Results: In the CERAD testing, PD patients exhibited deficits in the domains of se-
mantic memory, attention, visuospatial function, non-verbal memory and executive 
function. After correction for multiple testing, the performance of the subtests Figure 
Recall and Trail-Making Test A correlated significantly with FP-CIT uptake into the ipsi-
lateral executive subregion. The performance of the subtest Figure Saving correlated 
significantly with FP-CIT uptake into the contralateral executive subregion.
Conclusions: The significant correlation between cognitive function and density of 
nigrostriatal dopamine transporters, as assessed by FP-CIT SPECT, indicate that stri-
atal dopaminergic pathways—primarily the executive striatal subregion—are relevant 
to cognitive processing in PD.
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antidepressants, atypical antipsychotics and cholinesterase inhibi-
tors have a positive effect on the non-motor symptoms, therapeu-
tic responses are frequently suboptimal. This remains a major area 
of unmet therapeutic need.2
A considerable percentage (20%-50%) of patients with PD de-
velop cognitive deficits resulting in mild cognitive impairment (MCI) 
or dementia in the later stages of the disease.3-7 Cognitive deficits in 
PD are explained by the dual syndrome hypothesis:8,9 PD is charac-
terized as a synucleinopathy with pathogenic aggregation of α-synu-
clein and the formation of Lewy bodies. This degeneration involves 
(a) dopaminergic and (b) cholinergic neurotransmission,10 thus the 
term dual syndrome hypothesis. The degeneration of both dopami-
nergic and cholinergic pathways appears to contribute to cognitive 
deficits in PD. For example, the cholinesterase inhibitor rivastigmine 
alleviates MCI and dementia in PD.1,11 The lack of dopamine results 
in a fronto-striatal dysexecutive syndrome.9 Dopaminergic medica-
tion improves verbal fluency, working memory, visuospatial function 
and executive function in PD patients.12-16
The degeneration of the nigrostriatal dopaminergic pathway can 
be visualized by means of FP-CIT SPECT. Previous studies reported 
a correlation between striatal FP-CIT binding and cognitive function 
in selected PD patients: the striatal FP-CIT uptake correlated with 
executive function in de novo PD patients.17-19 Striatal FP-CIT bind-
ing correlated with attention/working memory, executive and visu-
ospatial function in de novo PD patients with and without MCI.20 
Global cognitive function correlated with striatal FP-CIT binding in 
non-demented PD patients.21 Striatal FP-CIT binding also correlated 
with frontal, executive and visuospatial function in patients with ad-
vanced PD and MCI.22 All these studies included selected PD pa-
tients (selection criteria: de novo or advanced PD, with or without 
MCI, non-demented).
In the present study, we applied FP-CIT SPECT to investigate 
the impact of nigrostriatal dopaminergic degeneration on cognitive 
function in an unselected cohort of PD patients. Since we aimed to 
correlate cognitive function with the functional integrity of striatal 
dopaminergic pathways, we structured the striatum according to the 
study of Tziortzi et al,23 which subdivided the striatum into func-
tionally defined subregions—limbic subregion, executive subregion 
and sensorimotor subregion—based on striato-cortical anatomical 
connectivity derived from diffusion magnetic resonance imaging 
and probabilistic tractography in healthy subjects. This connectiv-
ity-based parcellation does not match the traditional anatomical, 
structure-based subdivision of the striatum.
2  | METHODS
2.1 | Subjects
The study involved 54 patients with idiopathic PD (age: 44-85 years, 
mean ± SD: 68 ± 10 years, 18 women, 36 men). PD was diagnosed 
according to the UK Brain Bank criteria.24 Three patients were at 
Hoehn and Yahr (H&Y) stage 1, 25 at H&Y stage 2, 11 at H&Y stage 3, 
14 at H&Y stage 4 and one at H&Y stage 5. In the “off state” (=with-
out effect of antiparkinsonian medication), the patients reached 
19 ± 7 points (mean ± SD) in the motor part (part III) of the Unified 
Parkinson’s Disease Rating Scale (UPDRS). Concerning the predomi-
nant motor type, 26 patients belonged to the akinetic-rigid type, 13 
patients to the tremor dominant type and 15 patients to the equiva-
lence type. The duration of PD was 3-19 years (8.3 ± 4.6 years, 
mean ± SD).
Patients were excluded from the study if they were taking cho-
linesterase inhibitors, anticholinergic drugs, serotonin or noradrena-
lin reuptake inhibitors. Further exclusion criteria included pregnancy 
or breastfeeding, a partner who was capable of childbearing, current 
or previous cerebral disease (except PD), psychiatric disorders or se-
vere medical conditions. Antiparkinsonian medication was paused 
before the CERAD testing since dopaminergic medication influences 
cognitive function in PD patients.12-16
No healthy controls were included in the study. The study proto-
col was approved by the local ethics committee (Ärztekammer des 
Saarlandes). All participants gave written informed consent prior to 
enrolment in the study.
2.2 | [123I]FP-CIT SPECT
Cerebral SPECT imaging of dopamine transporter was performed with 
the use of 123I-FP-CIT (123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-
(3-fluoropropyl)nortropan) (DaTscan®, GE Healthcare). After thyroid 
gland blocking with perchlorate (Irenat®, Alliance Pharma (Ireland) 
Limited), 185.1 ± 12.9 MBq 123-I-FP-CIT (mean ± SD) was admin-
istered intravenously, followed by 4 hours uptake time to SPECT 
acquisition. SPECT were performed using a triple-head Siemens 
Multispect 3 gamma camera (Siemens) equipped with low-energy 
high-resolution collimators. Data were acquired in a 128 × 128 ma-
trix covering 120 degrees per camera head, 40 seconds per view. We 
acquired a total of 120 views. An energy window of 158 keV ± 15% 
was applied. SPECT data were iteratively reconstructed by the use of 
3D ordered subsets expectation-maximization algorithm (four itera-
tions, 15 subsets, Butterworth filtering 10th order with 0.6 cut-off 
frequency, voxel size 3.2 × 3.2 × 3.2 mm) and attenuation corrected 
by Chang’s method.25 Reconstruction, registration and semiquan-
titative analysis were automatically performed using DaTQUANT®, 
(v.1.01, GE Medical Systems Israel), being an established state of 
the art software for dopamine transporter imaging. With automati-
cally placed, fixed sized volume of interest (VOI) auto-contouring by 
DaTQUANT®, 123I-FP-CIT uptake was measured for the executive 
subregion, the limbic subregion and the sensorimotor subregion of 
both striata. The executive subregion, limbic subregion and sensori-
motor subregion were identified by means of the three subdivided 
striatal connectivity atlas of Tziortzi et al.23 For all subregions, a sub-
region-to-background binding ratio was calculated. An automatically 
drawn VOI in the occipital cortex was used as background.
The measured values in the PD patients were compared to a 
normal data set provided by the vendor, which was comprised of 
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196 healthy subjects from the multicenter Parkinson Progression 
Markers Initiative study.26
2.3 | CERAD testing
The initial version of CERAD, the CERAD-NP test, was developed 
by the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD).27 The CERAD-NP test includes neuropsychological sub-
tests: Verbal Fluency, Modified Boston Naming Test, Mini-Mental 
State Examination, Word List (Learning, Recall, Intrusions and Saving) 
and Visuoconstructive Ability (Figures Drawing, Figures Recall and 
Figures Saving). The CERAD-NP test was developed in English; so, 
for German-speaking people, the Memory Clinic of the University 
Hospital of Basel (Switzerland) created a German version called the 
CERAD Plus test.28 In addition to the CERAD-NP test, the CERAD 
Plus test includes the subtests Trail-making Test A, Trail-making Test 
B and Phonemic Fluency s-words. All patients in our study underwent 
the CERAD Plus test. The subtests are explained in detail below:
• Verbal Fluency: The subject must name as many animals as possi-
ble within 1 minute and is awarded one point for each animal. This 
subtest examines verbal velocity and capacity, semantic memory, 
speech, executive function and cognitive flexibility.
• Modified Boston Naming Test: 15 drawings of daily objects are 
shown, which the subject must name within 10 seconds. The 
maximum score is 15 points (one point for each correctly named 
drawing). This subtest examines visual perception and reveals 
word-finding difficulties.
• Mini-Mental State Examination (MMSE): The MMSE is often used 
solely as a screening test for dementia (up to 30 points). It has 
been integrated into CERAD-NP testing to examine orientation 
(to person, place and time), memory, attention, calculating capac-
ity and speech.
• Word List (Learning, Recall, Intrusions, Saving and Recognition): In the 
first step (Word List Learning), 10 words are read out to the subject, 
who must memorize them and directly reproduce the words within 
90 seconds. This procedure is repeated three times with the same 
words but with the word order changed (up to 3 × 10 points). The 
percentage of words remembered in the three runs altogether is de-
fined as Word List Saving. After an interval, in which another subtest 
is performed, the same words are asked again (Word List Recall; up 
to 10 points). The term Word List Intrusions denotes wrongly remem-
bered words, which are produced by the subject although they have 
not been read out by the examiner. In a further step, 20 words, the 
10 words from the first step (old words) and 10 new words, are read 
out to the subject. The subject has to identify the 10 old words (up 
to 10 points) and the 10 new words (also up to 10 points, Word List 
Recognition). The subtest Word List examines learning capacity and 
memory for language information.
• Figure Drawing: The subject must draw four figures of increasing 
difficulty (up to 11 points depending on the accuracy of the drawn 
figure). This subtest examines visuoconstructive ability. After an 
interval, in which two other subtests are performed, all four fig-
ures must be drawn from memory (Figure Recall, up to 11 points). 
The percentage of figures remembered is defined as Figure Saving. 
These Figure Recall/Figure Saving subtests investigate non-verbal 
memory.
• Phonemic Fluency “s”-words: Subjects must say as many words as 
possible beginning with the consonant “s” within 1 minute. For 
each word, the subject gets one point. This subtest examines 
strategy-oriented verbal fluency.
• Trail-making Test A: The subject must connect neighbouring num-
bers in ascending order (eg, 1 – 2 – 3 – 4 – 5 etc) by drawing a line 
between them. The numbers are randomly and widely distributed 
over a whole page. The examiner measures the time needed for 
this test which examines psychomotor velocity. Trail-making Test 
B: The subject must connect numbers and letters alternately in 
ascending order (eg, 1 – A – 2 – B – 3 – C – 4 – D – 5 – E etc) 
by drawing a line between them. Again, the time needed for this 
test is measured. The Trail-making Tests A and B and the quotient 
Trail-making Test B/A reflect the integrity of executive function.
The results of the individual subtests can be expressed in two 
ways: as an absolute value or as a relative value (=z-score). The ab-
solute value gives the number of points, that were obtained in a 
subtest, or the time, which was needed for a subtest (for example in 
the trail-making tests). The performance (= absolute value) of each 
patient in each subtest was standardized according to a normal 
population of the same age, sex and educational standard, result-
ing in a relative value (z-score). The relative value is expressed as a 
standard deviation (SD) of the mean value of the normal population. 
For example, a relative value of +1.0 (SD) means that the individual 
subject is better than 68% of the healthy volunteers of the same 
age, sex and educational standard. A relative value of −2.0 (SDs) 
means that the individual subject is worse than 95% of the compa-
rable healthy volunteers, etc The CERAD testing was performed by 
a neurologist who was blinded to the results of the FP-CIT SPECT.
2.4 | Statistical analysis
Descriptive data are given as mean and SD. We correlated the 
15 subtests of the CERAD testing with FP-CIT uptake in all six 
studied brain regions—limbic subregion, executive subregion and 
sensorimotor subregion on both sides—resulting in 15 × 6 = 90 
correlations. The correlations were corrected for severity of 
motor symptoms, which was measured by part III (motor part) of 
the UPDRS. We performed this correction in order to exclude any 
effects of parkinsonian motor symptoms on the correlations. The 
correction was calculated using partial correlation analysis for 
normally distributed data. In the case of not normally distributed 
data, we used the ordinal regression analysis. Since multiple cor-
relations were calculated from the same data, we performed a cor-
rection for multiple testing using the false discovery rate (FDR) 
after the Benjamini-Hochberg procedure.29
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3  | RESULTS
3.1 | Performance of the CERAD testing
The 54 investigated PD patients showed, on average, a normal in-
dividual performance—standardized to a normal population of the 
same age, sex and educational standard—in the subtests Modified 
Boston Naming Test, Word List Learning, Word List Recall, Word List 
Intrusions, Word List Saving, Word List Recognition and Phonemic 
Fluency “s” words (Table 1). All subtests resulting in normal perfor-
mance study verbal function.
Performance was impaired, compared with a normal popu-
lation, in the subtests Verbal Fluency, MMSE, Figure Drawing, 
Figure Recall, Figure Saving, Trail-making Test A and Trail-making 
Test B. These subtests examine semantic memory, attention, vi-
suospatial function, non-verbal memory and executive function. 
In no subtest were the 54 PD patients clearly better than the nor-
mal population.
3.2 | FP-CIT SPECT
The 54 PD patients had a significantly lower FP-CIT uptake into 
all three subregions (limbic subregion: 1.79 ± 0.28 [mean ± SD], 
executive subregion: 2.24 ± 0.29 and sensorimotor subregion: 
1.30 ± 0.26, n = 108 each [n = 108 due to both sides in 54 PD pa-
tients]) than the healthy controls (limbic subregion: P < .05, execu-
tive subregion: P < .05, sensorimotor subregion: P < .01, unpaired 
t test each).
In addition, the FP-CIT uptake can be expressed by relative val-
ues (=z-scores) compared to healthy control group. For example, a 
relative value of +1.0 (SD) means that the FP-CIT uptake is higher 
than in 68% of the healthy subjects. A relative value of −2.0 (SDs) 
means that the FP-CIT uptake is lower than in 95% of the healthy 
subjects. In our PD patients, the relative values (z-scores)—compared 
to the normal data set provided by the vendor—were −1.92 ± 1.40 
(range −4.72 up to +0.76 [minimum up to maximum]) for the limbic 
subregion, −0.86 ± 1.18 (range −4.55 up to +1.71) for the executive 
subregion and −2.32 ± 1.78 (range −5.28 up to +1.21) for the senso-
rimotor subregion (n = 108 each).
The following calculations were performed with the absolute 
values of FP-CIT binding. There was no correlation between age 
and striatal FP-CIT binding (age vs contralateral limbic subregion: 
r = −.05, P = .86, age vs ipsilateral limbic subregion: r = −.14, P = .31, 
age vs contralateral executive subregion: r = −.06, P = .78, age vs 
ipsilateral executive subregion: r = −.11, P = .49, age vs contralateral 
sensorimotor subregion: r = −.10, P = .46 and age vs ipsilateral sen-
sorimotor subregion: r = −.14, P = .34). The term “ipsilateral” denotes 
the striatal subregion ipsilateral to the body side, which was clinically 
more affected by parkinsonian motor symptoms. Analogous to this, 
the term “contralateral” means the striatal subregion contralateral 
to the body side, which was clinically more affected by parkinsonian 
motor symptoms.
3.3 | Correlation between CERAD testing and 
cerebral FP-CIT binding
We correlated performance in the individual 15 CERAD subtests, 
expressed in z-scores, with local FP-CIT binding, as determined by 
FP-CIT uptake, in six brain areas (limbic subregion, executive subre-
gion and sensorimotor subregion on both sides each). Consequently, 
we obtained 15 × 6 = 90 correlations. These correlations were cor-
rected for severity of motor parkinsonian symptoms, which were 
measured by the motor part of the UPDRS score. In 14 of these 90 
correlations, we found a P-value of <.05 (P < .05):
• Correlation of FP-CIT uptake in ipsilateral limbic subregion with 
performance of Figure Recall (r = +.42, P = .005) and Figure 
Saving (r = +.48, P = .005).
• Correlation of FP-CIT uptake in contralateral limbic subregion with 
performance of Figure Recall (r = +.37, P = .028) and Figure Saving 
(r = +.41, P = .019).
TA B L E  1   Performance in the single CERAD subtests
CERAD subtest Mean SD
Range
(min/max) P-value
Verbal Fluency −0.54 1.27 −3.40/+2.23 .004
Modified Boston 
Naming Test
−0.10 1.11 −4.15/+1.51 .593
Mini-Mental State 
Examination
−1.22 1.69 −8.29/+1.14 <.001
Word List Learning −0.30 1.23 −4.38/+1.76 .076
Word List Recall −0.09 1.16 −2.82/+2.47 .488
Word List Intrusions +0.04 0.98 −2.97/+0.95 .688
Word List Saving +0.01 1.31 −3.61/+3.56 .862
Word List 
Recognition
−0.12 1.24 −4.48/+1.23 .415
Figure Drawing −0.40 1.11 −2.95/+1.26 .017
Figure Recall −0.68 1.25 −3.82/+1.43 .001
Figure Saving −0.46 1.04 −3.10/+2.11 .004
Trail-making Test A −0.71 1.33 −3.44/+2.46 <.001
Trail-making Test B −0.51 1.13 −2.94/+2.25 .002
Phonemic Fluency 
s-words
−0.16 1.26 −3.78/+2.16 .568
Note: The column “Mean” contains the mean of the relative values of 
all 54 PD patients in the individual subtests (mean z-score). A relative 
value of 0 represents an individual performance which is identical 
to the average of a normal population with the same age, sex and 
educational standard. A relative value of −1 represents an individual 
performance, which is one standard deviation lower than that of the 
normal population. The column “SD” contains the standard deviation of 
the relative values of all 54 PD patients in the single subtests. Note: the 
high standard deviation ≥0.98 for all subtests, which indicates high inter-
individual variability. Range: The minimum value (min) and maximum 
value (max) are given (minimum/ maximum). P-value = P-values for the 
mean z-score being different from zero (t test for one sample).
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• Correlation of FP-CIT uptake in ipsilateral executive subregion with 
performance of Word list Recall (r = +.32, P = .030), Figure Recall 
(r = +.48, P = .001), Figure Saving (r = +.36, P = .022) and Trail-
Making Test A (r = +.49, P = .001).
• Correlation of FP-CIT uptake in contralateral executive subregion 
with performance of Word List Recall (r = +.35, P = .019), Figure 
Recall (r = +.40, P = .017), Figure Saving (r = +.51, P < .001, 
Figure 1) and Trail-Making Test A (r = +.40, P = .021).
• Correlation of FP-CIT uptake in ipsilateral sensorimotor subregion 
with performance of Figure Recall (r = +.36, P = .021).
• Correlation of FP-CIT uptake in ipsilateral sensorimotor subregion 
with performance of Figure Recall (r = +.33, P = .041).
The correlation coefficients of FP-CIT uptake in all subre-
gions with performance of Word List Recall were calculated 
with the partial correlation analysis. For all other calculations 
coefficients, the ordinal regression analysis was used. The 14 
correlation coefficients with a P-value < .05 indicate that the 
performance of the according subtests improved with an in-
creasing FP-CIT uptake in the respective striatal subregion. In 
the remaining 76 of 90 correlation coefficients, the P-value was 
equal or higher than .05.
Since we calculated 15 × 6 = 90 correlations, we performed 
a correction for multiple testing by means of the FDR after the 
Benjamini-Hochberg procedure. This correction for multiple testing 
disclosed the following three significant correlations (P < .05, FDR 
after the Benjamini-Hochberg procedure):
• FP-CIT uptake in ipsilateral executive subregion vs performance 
of Figure Recall;
• FP-CIT uptake in ipsilateral executive subregion vs performance 
of Trail-Making Test A;
• FP-CIT uptake in contralateral executive subregion vs perfor-
mance of Figure Saving.
4  | DISCUSSION
In our study, PD patients showed a significantly impaired perfor-
mance in the domains of semantic memory (measured by the subtest 
Verbal Fluency), attention (Mini-Mental State Examination), visuos-
patial function (Figure Drawing), non-verbal memory (Figure Recall, 
Figure Saving) and executive function (Trail-making Test A and 
Trail-making Test B). Similar cognitive deficits—primarily memory 
impairment, visuospatial dysfunction, attention/ working memory 
impairment and executive dysfunction—in non-demented PD pa-
tients were reported by previous studies.30-33
The measurement of the density of presynaptic dopamine trans-
porters by means of FP-CIT SPECT enables correlation of cognitive 
function with the dopaminergic striatal function. We did not subdi-
vide the striatum after anatomical criteria but by functional crite-
ria according to the three subdivided striatal connectivity atlas of 
Tziortzi et al.23 Tziortzi et al23 applied diffusion magnetic resonance 
imaging and probabilistic tractography with the aim to obtain stria-
to-cortical anatomical connectivity information. On the basis of this 
striato-cortical connectivity information, the striatum mainly con-
sists of a limbic subregion, an executive subregion and a sensorim-
otor subregion. This functional parcellation of the striatum differs 
from its anatomical structure-based subdivision.
We found in all three striatal subregions—limbic subregion, ex-
ecutive subregion and sensorimotor subregion—a significantly lower 
FP-CIT uptake in PD patients than in the healthy controls. After 
correction for multiple testing, there were significant correlations 
between striatal FP-CIT uptake into the ipsilateral executive subre-
gion and the performance of the CERAD subtests Figure Recall and 
Trail-Making Test A as well as between striatal FP-CIT uptake into 
the contralateral executive subregion and the performance of the 
CERAD subtest Figure Saving. Compared to the healthy control pop-
ulation, the PD patients had a significantly worse performance in the 
subtests Figure Recall, Figure Saving and Trail-Making Test A. These 
F I G U R E  1   Correlation of the CERAD 
subtest Figure Saving with the FP-CIT 
uptake in the contralateral executive 
subregion. Each patient is represented by 
a blue circle. The performance of Figure 
Saving is expressed in z-scores (relative 
values)
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data suggest that the impaired dopaminergic function of the ipsi- 
and contralateral executive subregion may contribute to an impaired 
performance of non-verbal memory and executive function in PD.
Tziortzi et al23 found bilaterally symmetric projections of the 
cortical areas to the striatum. This might explain why we detected 
significant correlations for both ipsi- and contralateral executive re-
gions and not only for the contralateral executive region. The ex-
ecutive subregion of the striatum receives a strong dopaminergic 
input from the prefrontal cortex and a smaller dopaminergic input 
from the parietal lobe.23 This strong dopaminergic input from the 
prefrontal cortex, which plays an important role for executive func-
tion, may explain the close correlation between FP-CIT uptake into 
the striatal executive region and performance of executive function 
(subtest Trail-Making Test A). The parietal lobe is a functionally het-
erogeneous area, which includes executive, visual, somatosensory 
and limbic subregions.23 It might be speculated that the small input 
from the parietal lobe into the striatal executive region influences 
the significant correlation between FP-CIT uptake into the striatal 
executive region vs non-verbal memory (subtest Figure Saving). The 
significant results according to the executive striatal subregion sug-
gest that impairment of the dopaminergic striatal executive path-
ways contribute to cognitive deficits in PD.
In PD patients, the other striatal subregions—the limbic subre-
gion and the sensorimotor subregions—also had a significantly lower 
FP-CIT uptake than in the healthy controls. However, after correc-
tion for multiple testing, we could not find any significant correlation 
between the performance of any CERAD subtest and the FP-CIT 
uptake into any limbic or sensorimotor subregion. Since the stria-
tal executive subregion overlaps with the limbic and sensorimotor 
subregion,23 one would expect significant correlations between 
cognitive function and the dopaminergic function of the limbic and 
sensorimotor subregion, too. The reason for this missing correlation 
is unclear. It can be speculated that in another population of PD pa-
tients—for example only PD patients with cognitive deficits (MCI 
and/or beginning dementia)—several correlations would become 
more evident.
For some CERAD subtests—Verbal Fluency, Modified Boston 
Naming Test, Mini-Mental State Examination, Word List Intrusions, 
Word List Saving, Word List Recognition, Figure Drawing, Trail-
making Test B and Phonemic Fluency “s” words—correlation of the 
performance of the subtest with the FP-CIT uptake of any striatal 
subregion was not significant (P > .05). It might be postulated that 
these cognitive functions are mainly mediated via transmitters other 
than dopamine, for example via the transmitter acetylcholine. A 
previous nuclear medicine study34 reported a significant correlation 
between the performance of the subtests Modified Boston Naming 
Test and Word List intrusions vs the acetylcholine receptor bind-
ing in cortical areas (right superior parietal lobule) and subcortical 
areas (left thalamus, right and left posterior subcortical region) in 
PD patients.
The relevant impact of both dopaminergic and cholinergic neu-
rodegeneration on cognition in PD is reflected by the dual syn-
drome hypothesis,8,9 which is supported by clinical data and nuclear 
medicine studies: the cholinesterase inhibitor rivastigmine alleviates 
MCI and dementia in PD.11 On the other hand, dopaminergic med-
ication improves certain cognitive functions—verbal fluency, work-
ing memory, visuospatial function and executive function—in PD 
patients.12-16 FP-CIT studies showed a correlation between striatal 
FP-CIT uptake and cognitive function—primarily executive and visu-
ospatial function—in PD patients.17-22
In summary, our results show that striatal dopaminergic degener-
ation—primarily of the executive subregion—contributes to cognitive 
deficits in PD. Dopaminergic medication appears to be a beneficial 
therapeutic intervention to improve cognitive deficits in PD.
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